Streetbeat News

Analyst Ratings

TOVX

Theriva Biologics (NYSE:TOVX) has announced the presentation of Phase 1 data from a study evaluating VCN-01 in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck. The study, conducted in collaboration with the Institut Catala d'Oncologia, showed enhanced patient survival, correlating with VCN-01 induced upregulation of PD(L)-1. The data will be presented at the European Society for Medical Oncology Congress in October 2023.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:31 pm

CHH

Morgan Stanley analyst Stephen Grambling maintains an Equal-Weight rating on Choice Hotels Intl (NYSE:CHH) and raises the price target from $137 to $139.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:30 pm

CART

Stifel analyst Mark Kelley has initiated coverage on Maplebear (NASDAQ:CART) with a Buy rating and a price target of $48.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:29 pm

CRWD

GLDM

HUM

NKE

On CNBC's 'Halftime Report Final Trades', Bryn Talkington recommended SPDR Gold MiniShares (GLDM) as gold futures jumped 3.3%. Stephen Weiss picked Humana Inc. (HUM) following the announcement of CEO Bruce Broussard's planned departure in 2024. Jim Lebenthal suggested NIKE, Inc. (NKE) due to its strong holiday season prospects. Joseph Terranova recommended CrowdStrike Holdings, Inc. (CRWD) which recently hit a 52-week high.

Portfolio Pulse from Lisa Levin

October 16, 2023 | 12:28 pm

BLK

Morgan Stanley analyst Mike Cyprys has maintained an Overweight rating on BlackRock (NYSE:BLK) and raised the price target from $836 to $897.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:23 pm

DHI

Goldman Sachs has upgraded D.R. Horton's stock from Neutral to Buy, leading to a rise in the company's shares.

Portfolio Pulse from Bill Haddad

October 16, 2023 | 12:22 pm

T

AT&T Inc. (NYSE:T) is set to release its latest quarterly earnings on Thursday, Oct. 19. Options markets are predicting a +/-5% move in AT&T's stock post the earnings release. A buyer purchased 3,324 of the Jan. 15-calls at an average price of 50 cents per contract, indicating an expectation that AT&T's stock will trade above $15.50 by January expiration. Analysts predict the telecom's quarterly earnings to be at 62 cents per share on revenue of $30.19 billion.

Portfolio Pulse from Lisa Levin

October 16, 2023 | 12:22 pm

AAPL

Morgan Stanley analyst Erik Woodring has maintained an Overweight rating on Apple (NASDAQ:AAPL) but lowered the price target from $215 to $210.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:20 pm

ENTX

Entera Bio Ltd. (NASDAQ:ENTX) presented two posters at the Annual Society of Bone and Mineral Research (ASBMR) 2023 Annual Meeting, showcasing the consistent delivery and rapid biological responses of its oral PTH(1-34) peptide in a mini tablet format. The company's lead drug candidate, EB613, is being developed as a once-daily oral therapy for osteoporosis. A Phase 2 study showed that EB613 produced rapid changes in biochemical markers and increased Bone Mineral Density in postmenopausal women with osteoporosis. A Phase 1 study comparing oral EB613 and other treatments is ongoing.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:20 pm

ZYXI

RBC Capital analyst Shagun Singh has initiated coverage on Zynex (NASDAQ:ZYXI) with an Outperform rating and a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 12:19 pm